New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
06 mars 2024 07h30 HE
|
Biogen Inc.
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker complement...
Neurological Biomarkers Market Worth $14.45 Billion by 2027 – Comprehensive Report by The Insight Partners
30 oct. 2023 07h32 HE
|
The Insight Partners
Pune, India, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Biomarkers are the molecules that indicate the presence of a disease. The biomarkers of the neurological disorders were not that accessible in earlier...
Newborn Screening Market Worth $2.48 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
09 oct. 2023 08h45 HE
|
The Insight Partners
Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Newborn screening involves testing a newborn for serious medical conditions and certain harmful or potentially fatal disorders that are not apparent at...
Camelot Portfolios Announces Cash Alternatives and Hedging Strategies
30 mars 2023 15h19 HE
|
Camelot Portfolios LLC
MAUMEE, Ohio, March 30, 2023 (GLOBE NEWSWIRE) -- Camelot Portfolios today announces an expanded lineup of cash alternatives and hedging strategies to help Investment Advisors serve clients seeking...
Robotic Legs Will Help Children Walk for the First Time at Toronto Area Facility
12 juil. 2022 14h00 HE
|
Trexo Robotics
TORONTO, July 12, 2022 (GLOBE NEWSWIRE) -- Thanks to an outpouring of community support, Kayla’s Children Centre won Trexo Robotics’ Canada- wide Trexo Plus Robotic Gait Trainer Giveaway. ...
Enhanced Profiles Drive BlackRock, Invesco and Boutique Managers to The Wealth Advisor's New Model Portfolio Selection Guide
22 oct. 2021 14h03 HE
|
The Wealth Advisor
SANTA MONICA, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- The Wealth Advisor, a Marina Media LLC publication, today announced the upcoming launch of the first Model Portfolio & SMA Strategists:...
La réaction de Biogen aux recommandations mises à jour de l’ACMTS concernant l’accès à SPINRAZA
01 mars 2019 20h18 HE
|
Biogen Canada
·L’Agence canadienne des médicaments et des technologies de la santé (ACMTS) a élargi ses recommandations concernant le financement par les fonds publics du traitement des patients atteints...
Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
01 mars 2019 20h18 HE
|
Biogen Canada
·Canadian Association of Drugs and Technologies in Health (CADTH) has expanded their recommendations for public reimbursement for SMA patients ·The recommendation, however, continues to limit access...
Biogen salue la décision du Québec de rembourser SPINRAZAMC (nusinersen) pour une vaste population de patients atteints d’amyotrophie spinale (AS)
20 déc. 2018 12h19 HE
|
Biogen Canada
MISSISSAUGA, Ontario, 20 déc. 2018 (GLOBE NEWSWIRE) -- Cette décision découle de la recommandation positive de l’Institut national d’excellence en santé et services sociaux (INESSS) qui...
Biogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients
20 déc. 2018 12h19 HE
|
Biogen Canada
The decision follows positive recommendation from the Institut national d'excellence en santé et services sociaux (INESSS) recognising the urgency and need for a treatment for patients with SMA and...